We value your privacy

We use cookies to enhance your browsing experience, serve personalized ads or content, and analyze our traffic. By clicking "Accept All", you consent to our use of cookies. Cookie Policy

Customize Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

No cookies to display.

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

No cookies to display.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

No cookies to display.

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

No cookies to display.

Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.

No cookies to display.

Africanian
  • News
  • News 24/7
  • Politics
  • Business
  • Health
  • Sports
  • Travel
  • World
    • US
    • Russia
    • Europe
    • Asia
    • America
  • Events
No Result
View All Result
Africanian
  • News
  • News 24/7
  • Politics
  • Business
  • Health
  • Sports
  • Travel
  • World
    • US
    • Russia
    • Europe
    • Asia
    • America
  • Events
No Result
View All Result
Africanian
No Result
View All Result
Home World

Introducing ‘Vaxzevria’: AstraZeneca renames Covid vaccine as firm fights off controversy over drug

AstraZeneca has renamed its Covid-19 vaccine, a move that coincides with the company’s struggle to reassure the public that its drug is safe, following numerous reports of potential adverse effects.

africanian
March 30, 2021
in World
1 0
0
Introducing ‘Vaxzevria’: AstraZeneca renames Covid vaccine as firm fights off controversy over drug
Share on FacebookShare on TwitterShare via Whatsapp
The British-Swedish pharmaceutical has rebranded its jab, which previously went by the simple ‘AstraZeneca Covid-19 Vaccine’, to ‘Vaxzevria’. In a press release, the company said that the name change does not involve any alterations to the actual drug. Medical workers should be made aware of the rebrand though, the firm said, because the labeling and packaging can look different.

The European Medicines Agency signed off on the new name last week after AstraZeneca sought approval for the change from the EU regulator. Covishield, which is based on the same formula but was developed in collaboration with the Serum Institute of India, will retain its current branding.

The debut of ‘Vaxzevria’ comes as AstraZeneca fends off growing uncertainty about its drug, which was created in tandem with Oxford University. More than a dozen countries across Europe have temporarily halted their rollout of the vaccine following reports of blood clots. EU health officials, as well as the pharma firm, have maintained that the vaccine is safe and not related to the medical episodes, some of which led to death.

On Monday, Canada joined the growing list of countries that have suspended or placed restrictions on the drug’s use. Citing potential safety concerns, the country said that the vaccine would not be administered to people younger than 55.

The company was hit with more bad press after US regulators raised concerns that trial data used to gauge the efficacy of the vaccine was potentially outdated and misleading. AstraZeneca said that it was working to update and verify the trial’s findings. The vaccine has not yet been approved for emergency use in the United States.

Related Post

President Adesina at au-eu summit

African Development Bank Group President Calls for SDR reallocation and vaccine equality at EU-AU summit

February 18, 2022
Expired Covid-19 vaccines

Nigeria Rejects Donated COVID-19 Vaccines With Six Months Expiry Date

February 17, 2022

4th Pfizer, Moderna shot less effective against Omicron variant: Israeli study

January 18, 2022

Highlight: COVAX delivers its 1 billionth COVID-19 vaccine dose

January 16, 2022

Despite reassurances from the medical bodies and governments, Europeans appear to be growing increasingly distrustful of the AstraZeneca drug. A poll released by YouGov last Monday revealed that only 23% of French people and 32% of Germans consider the vaccine to be safe.

However, it’s not clear whether the ‘Vaxzevria’ name change was motivated by the bad publicity, as the trademark application for the drug dates back to December.

Source: rt.com
Tags: AstraZenecaCovid-19 vaccine
africanian

africanian

Related Posts

President Adesina at au-eu summit
News

African Development Bank Group President Calls for SDR reallocation and vaccine equality at EU-AU summit

by africanian.news
February 18, 2022
Expired Covid-19 vaccines
Health

Nigeria Rejects Donated COVID-19 Vaccines With Six Months Expiry Date

by africanian.news
February 17, 2022
4th Pfizer, Moderna shot less effective against Omicron variant: Israeli study
Health

4th Pfizer, Moderna shot less effective against Omicron variant: Israeli study

by africanian
January 18, 2022
No Result
View All Result

Africanian News

Is a dedicated project aimed at amplifying the voices of the African Ecosystem and Diaspora. We actively collaborate with initiatives to improve access to education and digital inclusion, both in traditional schools and through digital platforms, for African children.

It’s crucial to emphasize that none of the articles or images featured on our platform are intended for copyright infringement, neither now nor in the future. If you believe that any information, text, image, etc., may be subject to copyright and should be removed, please notify us by sending an email to info@africanian.com

Your dreams matter; your stories matter.

Feel free to explore collaboration opportunities with us. Share your articles, thoughts, interviews, experiments, or no-comment videos by reaching out to info@africanian.com. You can also subscribe to our mailing list to receive the latest updates from Africanian News.

News letter

© 2025 JNews - Premium WordPress news & magazine theme by Jegtheme.

Welcome Back!

Login to your account below

Forgotten Password? Sign Up

Create New Account!

Fill the forms below to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In

Log In

Sign In

Forgot password?

Don't have an account? Register

Forgot password?

Enter your account data and we will send you a link to reset your password.

Back to Login

Your password reset link appears to be invalid or expired.

Log in

Privacy Policy

Accept

Add to Collection

  • Public collection title

  • Private collection title

No Collections

Here you'll find all collections you've created before.

No Result
View All Result
  • News
  • Politics
  • Business
  • Health
  • Sports
  • Entertainment
  • Tech
  • Travel
  • World

© 2025 JNews - Premium WordPress news & magazine theme by Jegtheme.